Learn more about all the FDA-approved gene therapies we offer and the conditions we currently treat through our Pediatric Gene Therapy Program.
Who is eligible for pediatric gene therapy for neurological disorders?
Eligibility for pediatric gene therapy depends on the specific neurological condition and your child’s health history. If your child’s condition doesn’t have an FDA-approved gene therapy, one may be available as part of a clinical trial (research study). To find possible gene therapies for your child’s condition, you can search on clinicaltrials.gov. Clinicaltrails.gov is an online database maintained by the National Institutes of Health.
Is gene therapy a permanent cure for neurological disorders?
The gene therapies described on this page may be able to slow or stop neurological diseases from progressing, but they can’t reverse damage that has already happened. At Children’s Health, our neurology specialists provide complete care for children with neurological disorders – whether they’ve received gene therapy or not – to help them have their best possible quality of life.
Is pediatric gene therapy for neurological disorders safe?
The gene therapies we offer have been studied through years of preclinical safety studies and clinical trials. The FDA also reviews all the research data before people receive any therapy.
Gene therapies for neurological disorders are safe, but children do need intense monitoring after treatment to watch for possible side effects. Our care team has years of experience in working with these therapies to provide your child with the best possible care.
How old do you have to be to get gene therapy for neurological disorders?
The age ranges and other criteria vary depending on the specific neurological condition and gene therapy:
Elevidys - Boys ages 4 and older who have Duchenne muscular dystrophy with a confirmed mutation in the DMD gene and do not have a preexisting medical reason preventing treatment with this therapy
Lenmeldy - Children of any age who have early or presymptomatic metachromatic leukodystrophy
Skysona - Boys ages 4 through 17 who have early, active cerebral adrenoleukodystrophy
Zolgensma - Children under age 2 who have spinal muscular atrophy